Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Capital Expenditure for the year ending March 31, 2024: USD -1.38 M

Roivant Sciences Ltd. Capital Expenditure is USD -1.38 M for the year ending March 31, 2024, a 0.00% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Roivant Sciences Ltd. Capital Expenditure for the year ending March 31, 2024 was USD -1.38 M, a 89.11% change year over year.
Roivant Sciences Ltd. Capital Expenditure for the year ending March 31, 2023 was USD -12.69 M, a 27.22% change year over year.
Roivant Sciences Ltd. Capital Expenditure for the year ending March 31, 2022 was USD -17.44 M, a -200.31% change year over year.
Roivant Sciences Ltd. Capital Expenditure for the year ending March 31, 2021 was USD -5.81 M, a -18.10% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Vaccines

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years